CRSP CRISPR Therapeutics
- 55.650
- -0.760-1.35%
- 55.960
- +0.310+0.56%
CRISPR Therapeutics News
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(10.2%)
CRISPR Therapeutics | ARS: Annual Report to Security Holders
CRISPR Therapeutics | DEF 14A: Definitive information statements
CRISPR Therapeutics | DEFA14A: Others
CRISPR Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 10-K: Annual report
Analysis
Price Target
No Data
